Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dialysate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Dialysate. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-024449-65 Sponsor Protocol Number: 159:2010/526806 Start Date*: 2011-02-22
    Sponsor Name:Västerbottens läns landsting
    Full Title: Will there be lipid changes during dialysis with Citrasate as dialysate compared to conventional dialysis.
    Medical condition: Chronic haemodialysis patients 18 years upwards. Patients should be in a stable condition during their chronic dialysis program (no ongoing infections or active extensive tumour with CRP above 30 m...
    Disease: Version SOC Term Classification Code Term Level
    10066622 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003348-63 Sponsor Protocol Number: CBPS804A2204 Start Date*: 2013-02-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease
    Medical condition: Patients with chronic kidney disease stage 5D (CKD-5D) and evidence of mineral and bone disorder as judged by low serum intact PTH levels according to KDIGO guidelines
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005274-30 Sponsor Protocol Number: UCL_2011_DIDo Start Date*: 2012-08-27
    Sponsor Name:Université catholique de Louvain
    Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study
    Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10007184 CAPD LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018010-18 Sponsor Protocol Number: V1.0,29.11.2009 Start Date*: 2010-07-02
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin
    Full Title: Multiple-dose Pharmacokinetics of Doripenem during continuous venovenous hemodiafiltration and molecular adsorbent recirculating system in ICU patients and during hemodialysis in longterm hemodialy...
    Medical condition: pharmacokinetics of Doripenem during CVVHDF(intensive care patients continuous venovenous haemodiafiltration), MARS(extracorporeal liver assist device, using a hollow fiber dialysis column in which...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003364-21 Sponsor Protocol Number: MCI-196-E11 Start Date*: 2009-06-22
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Multicentre, Double-blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney D...
    Medical condition: Dislipidaemia in subjects with Chronic Kidney Disease on Dialysis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) DK (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000899-16 Sponsor Protocol Number: UMM022013TG Start Date*: 2013-10-16
    Sponsor Name:Department of Pharmacy Unversitätsmedizin Mainz
    Full Title: Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy
    Medical condition: Sepsis and acute renal failure (ARF) are pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated and ma...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021369-66 Sponsor Protocol Number: UMM062010FS Start Date*: 2010-11-16
    Sponsor Name:Department of Pharmacy Universitaetsmedizin Mainz
    Full Title: Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy
    Medical condition: Sepsis and acute renal failure (ARF) are two pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011505-16 Sponsor Protocol Number: 3.0 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin
    Full Title: Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis
    Medical condition: A total of 8 patients with renal insufficiency and treatment with automated peritoneal dialysis (APD) will be enrolled into this study evaluating the pharmacokinetics of fosfomycin in this special ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034660 Peritoneal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000421-31 Sponsor Protocol Number: Etelcalcetide-T50-CKD5D-2018 Start Date*: 2018-12-19
    Sponsor Name:Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3
    Full Title: A study to investigate the influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
    Medical condition: End stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003330-15 Sponsor Protocol Number: MCI-196-E10 Start Date*: 2007-01-30
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison wit...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003323-37 Sponsor Protocol Number: MCI-196-E07 Start Date*: 2007-01-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorpora...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004748-36 Sponsor Protocol Number: PA-CL-03A Start Date*: 2008-10-30
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label, randomized, active controlled multi center phase II dose finding study to evaluate the ability of PA21 to lower serum phosphate levels and the tolerability in patients with chronic k...
    Medical condition: Hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003324-11 Sponsor Protocol Number: MCI-196-E09 Start Date*: 2007-03-28
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004735-30 Sponsor Protocol Number: IH 003 Start Date*: 2006-11-20
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia.
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006535-53 Sponsor Protocol Number: MCI-196-E08 Start Date*: 2007-08-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphospha...
    Medical condition: Hyperphosphataemia and dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    9.1 10058108 Dyslipidaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005063-28 Sponsor Protocol Number: Emend2 Start Date*: 2013-10-02
    Sponsor Name:University of Gothenburg
    Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant
    Medical condition: End stage renal disease under treatment with peritoneal dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000791-42 Sponsor Protocol Number: JVM-GLU-12 Start Date*: 2012-07-26
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO LA PRINCESA
    Full Title: OPEN, RANDOMIZED AND CONTROLLED STUDY OF SAFETY AND VIABILITY, TO EVALUATE THE NEUROPROTECTIVE EFFECT OF PLASMA GLUTAMATE DIALYSIS IN ACUTE ISCHEMIC STROKE.
    Medical condition: BRAIN ISCHEMIC STROKE IN ACUTE PHASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000192-33 Sponsor Protocol Number: 20120360 Start Date*: 2013-07-12
    Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of A...
    Medical condition: Chronic Kidney Disease Secondary Hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10064848 Chronic kidney disease LLT
    17.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed) CZ (Completed) LV (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) EE (Completed) DE (Completed) GR (Completed) LT (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004958-18 Sponsor Protocol Number: 20130356 Start Date*: 2014-07-14
    Sponsor Name:Amgen, Inc.
    Full Title: A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Medical condition: Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) IT (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed) PT (Completed) DE (Completed) Outside EU/EEA GR (Completed) FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 21 09:28:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA